Literature DB >> 23212162

Surgery on extracorporeal circulation in early and advanced non-small cell lung cancer.

Matthias Kauffmann1, Tobias Krüger, Hermann Aebert.   

Abstract

BACKGROUND: Locally advanced (T4) non-small cell lung cancer (NSCLC) is principally amenable to surgery. For radical resection of cardiovascular structures, extracorporeal circulation (ECC) may be required. Tumor dissemination is a concern in this situation. In this study, we evaluate the long-term results of T4 NSCLC surgery with ECC and compare them with combined cardiopulmonary surgery for early-stage NSCLC and heart disease.
METHODS: We retrospectively analyzed 16 patients undergoing surgery on ECC over a 13-year period. Eight patients suffered from T4 NSCLC (group A), and another eight patients suffered from coincidental T1-T2 NSCLC and heart disease (group B).
RESULTS: In group A, five patients received neoadjuvant radiochemotherapy. Complete resection was achieved in all patients. Thirty-day mortality was one patient (12.5%) in each group. Six patients died from recurrent cancer with a median survival of 13.6 months in group A. Prognosis in patients with direct tumor invasion of the aortopulmonary window was a lot worse compared to those with atrial infiltration. One T4 patient who had only received surgery survived for 155 months without relapse. In group B, no NSCLC relapse occurred, and median survival was 21.6 months. All but one death in group B occurred due to cardiovascular incidents.
CONCLUSIONS: Surgery on ECC for T4 NSCLC gives satisfactory results. The site of infiltration appears to be most important for local tumor relapse. Long-term survival is possible in some cases. Simultaneous cardiac and pulmonary surgery resulted in good early and midterm outcomes without surgery-induced tumor propagation. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23212162     DOI: 10.1055/s-0032-1331041

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  7 in total

1.  Initial extended resection or neoadjuvant therapy for T4 non-small cell lung cancer-What is the evidence?

Authors:  Ilkka Ilonen; David R Jones
Journal:  Shanghai Chest       Date:  2018-10-11

Review 2.  Extended resections of non-small cell lung cancers invading the aorta, pulmonary artery, left atrium, or esophagus: can they be justified?

Authors:  Emily S Reardon; David S Schrump
Journal:  Thorac Surg Clin       Date:  2014-09-11       Impact factor: 1.750

3.  Liver resection using total vascular exclusion of the liver preserving the caval flow, in situ hypothermic portal perfusion and temporary porta-caval shunt: a new technique for central tumors.

Authors:  Daniel Azoulay; Umberto Maggi; Chetana Lim; Alexandre Malek; Philippe Compagnon; Chady Salloum; Alexis Laurent
Journal:  Hepatobiliary Surg Nutr       Date:  2014-06       Impact factor: 7.293

4.  Surgical outcome of patients with lung cancer involving the left atrium.

Authors:  Takuma Tsukioka; Makoto Takahama; Ryu Nakajima; Michitaka Kimura; Hidetoshi Inoue; Ryoji Yamamoto
Journal:  Int J Clin Oncol       Date:  2016-06-04       Impact factor: 3.402

5.  Management and postoperative outcome in primary lung cancer and heart disease co-morbidity: a systematic review and meta-analysis.

Authors:  George D Bablekos; Antonis Analitis; Stylianos A Michaelides; Konstantinos A Charalabopoulos; Anastasia Tzonou
Journal:  Ann Transl Med       Date:  2016-06

6.  Clinicopathological and prognostic significance of metastasis-associated protein 1 expression and its correlation with angiogenesis in lung invasive adenocarcinomas, based on the 2011 IASLC/ATS/ERS classification.

Authors:  Shuhai Li; Hui Tian; Weiming Yue; Lin Li; Cun Gao; Libo Si; Wensi Hu; Lei Qi; Ming Lu; Chuanle Cheng; Jingjing Cui; Guanqing Chen
Journal:  Oncol Lett       Date:  2015-10-29       Impact factor: 2.967

7.  Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma.

Authors:  Jiayuan Huang; Haizhu Song; Biao Liu; Bo Yu; Rui Wang; Longbang Chen
Journal:  J Exp Clin Cancer Res       Date:  2013-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.